Adenosine Diphosphate

Adenosine Diphosphate

SCHEMBL135142

Nc1ncnc2c1ncn2[C@@H]1O[C@@H](CO[P@@](=O)(O)OP(=O)(O)O)[C@H](O)[C@H]1O

nearest known ligand 0.92

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 7/20 0.92
P2RY2 P41231 4/20 0.92
P2RX1 P51575 4/20 0.92
P2RX3 P56373 4/20 0.92
SRC P12931 2/20 0.92
SMN1; SMN2 Q16637 2/20 0.92
P2RX2 Q9UBL9 2/20 0.92
ALDH1A1 P00352 2/20 0.92
P2RX4 Q99571 1/20 0.92
RNASEL Q05823 1/20 0.86
TRPM2 O94759 2/20 0.86
MACROD2 A1Z1Q3 1/20 0.86
SIRT6 Q8N6T7 1/20 0.86
MACROD1 Q9BQ69 1/20 0.86
TAS1R3 Q7RTX0 2/20 0.85
TAS1R1 Q7RTX1 2/20 0.85
DNPH1 O43598 1/20 0.85
PRKAB2 O43741 1/20 0.85
LDHA P00338 1/20 0.85
ADRB2 P07550 1/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adenosine Diphosphate SCHEMBL29979301 1.00 P2RY1 (0.92) P2RY1P2RY2P2RX1P2RX3SRC
Adenosine Diphosphate SCHEMBL14613190 1.00 P2RY1 (0.92) P2RY1P2RY2P2RX1P2RX3SRC
Adenosine Diphosphate SCHEMBL29358868 1.00 P2RY1 (0.92) P2RY1P2RY2P2RX1P2RX3SRC
Adenosine Diphosphate SCHEMBL24103 1.00 P2RY1 (0.92) P2RY1P2RY2P2RX1P2RX3SRC
Adenosine Diphosphate SCHEMBL18089780 1.00 P2RY1 (0.92) P2RY1P2RY2P2RX1P2RX3SRC
Adenosine Diphosphate SCHEMBL18785159 1.00 P2RY1 (0.92) P2RY1P2RY2P2RX1P2RX3SRC
Adenosine Diphosphate SCHEMBL12789537 1.00 P2RY1 (0.92) P2RY1P2RY2P2RX1P2RX3SRC
Adenosine Diphosphate SCHEMBL14180716 1.00 P2RY1 (0.92) P2RY1P2RY2P2RX1P2RX3SRC
Adenosine Diphosphate SCHEMBL195251 1.00 P2RY1 (0.92) P2RY1P2RY2P2RX1P2RX3SRC
Adenosine Diphosphate SCHEMBL29397735 1.00 P2RY1 (0.92) P2RY1P2RY2P2RX1P2RX3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 749 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612624-B2 Light-inducible CRISPR/Cas9 system for genome editing THE JOHNS HOPKINS UNIVERSITY (US) 2026-04-28 US claimed
CN-111755744-B Rapid lithium ion transmission material, and preparation method and application thereof 中国科学院宁波材料技术与工程研究所 2024-03-12 CN claimed
US-20230399376-A1 BINDING PROTEINS COMPRISING THE EXTRACELLULAR DOMAIN OF CD39 AND METHODS OF TREATING OR PREVENTING NEUROLOGICAL DISEASES BAKER HEART AND DIABETES INST (AU) 2023-12-14 US claimed
CN-116735850-A Convenient platelet function testing device, kit and method thereof 美高怡生生物电子科技(北京)有限公司 2023-09-12 CN claimed
US-20220403378-A1 LIGHT-INDUCIBLE CRISPR/CAS9 SYSTEM FOR GENOME EDITING THE JOHNS HOPKINS UNIVERSITY 2022-12-22 US claimed
CN-113655227-A Multi-connected detection kit for screening neonatal diseases, and preparation method and use method thereof 广州俊通生物科技有限公司 2021-11-16 CN claimed
US-11160866-B2 Biomaterials for delivery of blood extracts and methods of using same MOSAIC BIOSCIENCES, INC. (US) 2021-11-02 US claimed
CN-111635532-B Aggregation-induced fluorescence guest functionalized composite infinite coordination polymer nanoparticle and preparation and application thereof 华东师范大学 2021-07-27 CN claimed
WO-2021081469-A2 LIGHT-INDUCIBLE CRISPR/CAS9 SYSTEM FOR GENOME EDITING THE JOHNS HOPKINS UNIVERSITY (US) 2021-04-29 WO claimed
CN-111755744-A Rapid lithium ion transmission material and preparation method and application thereof 中国科学院宁波材料技术与工程研究所 2020-10-09 CN claimed
EP-0202094-A2 Process for producing physiologically active substance UNITIKA LTD. (JP) 1986-11-20 EP claimed
EP-0200541-A2 Immunochemical method and analytical composition and element for determination of creatine kinase-MB EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1986-11-05 EP claimed
US-4577012-A ABSORPTION ON ACTIVATED CARBON, ELUTION WITH ALKALI HYDROXIDE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1986-03-18 US claimed
EP-0071087-B1 IMPROVED DETERMINATION OF CREATINE PHOSPHOKINASE IN BODY FLUIDS SERAGEN DIAGNOSTICS, INC. (US) 1985-04-24 EP claimed
US-4473496-A Intramolecularly crosslinked hemoglobin THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 1984-09-25 US claimed
EP-0071087-A1 Improved determination of creatine phosphokinase in body fluids SERAGEN DIAGNOSTICS, INC. (US) 1983-02-09 EP claimed
US-4277562-A Stabilized liquid enzyme and coenzyme compositions MEDICAL ANALYSIS SYSTEMS, INC. 1981-07-07 US claimed
US-4271264-A Stabilized liquid enzyme and coenzyme compositions MEDICAL ANALYSIS SYSTEMS, INC. 1981-06-02 US claimed
US-4250254-A USING AN AQUEOUS VEHICLE, A MISCIBLE POLYOL SOLVENT, AND A POLYMER; PH; SHELF LIFE; MEDICAL DIAGNOSIS MEDICAL ANALYSIS SYSTEMS, INC. 1981-02-10 US claimed
US-4012286-A CLINICAL COLORIMETERS THE DOW CHEMICAL COMPANY (US) 1977-03-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11160866-B2 Biomaterials for delivery of blood extracts and methods of using same PDGFA, PGF, MATR3 P2RY1 3042/4885P2RY2 3128/4885P2RX1 3537/4885
US-12612624-B2 Light-inducible CRISPR/Cas9 system for genome editing RNMT, AMPD2, NT5C2 P2RY1 1518/4885P2RY2 798/4885P2RX1 1724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.